Key facts
- It has raised $50K; the latest was Early Stage VC in Nov 2025.
- Notable investors include Cambridge Enterprise Ventures, Accelerate Cambridge, Founders at the University of Cambridge.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Gastrobody Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Gastrobody Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gastrobody Therapeutics
Developer of orally delivered protein therapeutics designed to treat gastrointestinal conditions by applying protein agents. The company specializes in the engineering of ultrastable proteins that resist degradation in the gut and research and development of these proteins for disease targets in the gastrointestinal tract, enabling healthcare professionals to receive treatments that act directly, reduce systemic side effects, and potentially deliver therapy in oral form.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2025
- Employees
- 2
- Website
- gastrobodytx.com/
- Ownership
- Privately Held (backing)
Gastrobody Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gastrobody Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gastrobody Therapeutics in its N-PORT filings yet. We sweep new filings monthly.